标题
Guselkumab for the Treatment of Psoriasis
作者
关键词
-
出版物
BIODRUGS
Volume 32, Issue 2, Pages 119-128
出版商
Springer Nature
发表日期
2018-02-22
DOI
10.1007/s40259-018-0265-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Scanning the Immunopathogenesis of Psoriasis
- (2018) Andrea Chiricozzi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease
- (2017) Parakkal Deepak et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis
- (2017) G. Girolomoni et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
- (2017) Brian G Feagan et al. LANCET
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases
- (2016) George E. Fragoulis et al. Annual Review of Medicine
- First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
- (2016) Yanli Zhuang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])
- (2016) Bruce E. Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-12 protects from psoriasiform skin inflammation
- (2016) Paulina Kulig et al. Nature Communications
- Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- The Immunopathogenesis of Psoriasis
- (2015) Jaehwan Kim et al. DERMATOLOGIC CLINICS
- Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation
- (2015) Joseph R. Maxwell et al. IMMUNITY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
- (2015) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tavaborole: First Global Approval
- (2014) Anthony Markham DRUGS
- Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?
- (2014) Andrea Chiricozzi et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
- (2014) Howard Sofen et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
- (2012) Rosa Parisi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Interleukin 12 a Key Immunoregulatory Cytokine in Infection Applications
- (2010) Therwa Hamza et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
- (2009) L. van der Fits et al. JOURNAL OF IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started